Trial of THEO-260 in Ovarian Cancer Patients

This trial is testing THEO-260, a new experimental drug, in patients with advanced high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer that has come back after prior treatment. Early phases focus on safety and dosing, while later phases will assess how well the drug controls the cancer. **You may be eligible if...** - You have been confirmed to have advanced high-grade serous or endometrioid cancer of the ovary, fallopian tube, or peritoneum - You are in good general health (ECOG score 0–1) - You have measurable cancer on scans - Your life expectancy is more than 3 months - Your blood counts and organ function are adequate - For Part A: your cancer is platinum-resistant (progressed within 6 months of platinum chemotherapy) **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your organ function or blood counts don't meet the study requirements - You have other serious medical conditions that would interfere with participation Talk to your doctor to see if this trial is right for you.